Table 4 Response and outcomes results for regimens for the treatment of relapsed and refractory DLBCL.
From: Diffuse large B-cell lymphoma: new targets and novel therapies
Efficacy metric | Selinexor (n = 134) | Pola-BR (n = 40) | L-MIND (n = 81) | R-GemOX (n = 49) | R-GDP (n = 52) | R2 (n = 32) |
|---|---|---|---|---|---|---|
ORR, % | 29 | 45 | 57.5 | 61 | 63 | 28 |
CR, % | 13 | 40 | 40 | 44 | 31 | 22 |
mDOR (mo) | 9.3 | 12.6 | 34.6 | 10 | NR | 6 |
mPFS (mo) | 2.6 | 9.5 | 12.1 | 5 | 3 yr–31% | 2.8 |
mOS (mo) | 9.0 | 12.4 | 31.6 | 11 | 3 yr–66% | 10.2 |
